Selinexor Treatment of Refractory Myeloma

Inclusion Criteria:

Measurable MM based on modified IMWG guidelines. Defined by at least one of the following:

Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by quantitative IgA
Urinary M-protein excretion ≥ 200 mg/24 hours
Free Light Chain (FLC) ≥ 100 mg/L, provided that the FLC ratio is abnormal

If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative Ig levels by nephelometry or turbidimetry are acceptable

Must have previously received ≥ 3 anti-MM regimens including: an alkylating agent, lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, and a glucocorticoid. There is no upper limit on the number of prior therapies provided that all other inclusion/exclusion criteria are met.
MM refractory to previous treatment with one or more glucocorticoids, parenteral PI (i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide and/or pomalidomide), and the anti-CD38 mAb, daratumumab. Refractory is defined as ≤ 25% response to therapy, or progression during therapy or progression within 60 days after completion of therapy.

Exclusion Criteria:

Active smoldering MM.
Active plasma cell leukemia.
Documented systemic amyloid light chain amyloidosis.
Active CNS MM.